NCT02132260View on ClinicalTrials.gov

Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis

PHASE1CompletedINTERVENTIONAL
Enrollment

890

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions
Tinea Pedis
Interventions
DRUG

Naftifine Hydrochloride Cream 2%

Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks

DRUG

Naftin® (Naftifine Hydrochloride) Cream 2%

Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.

DRUG

Placebo Topical Cream

Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.

All Listed Sponsors
lead

Sun Pharmaceutical Industries, Inc.

INDUSTRY

NCT02132260 - Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis | Biotech Hunter | Biotech Hunter